Difference between revisions of "Heparin-induced thrombocytopenia"
Jump to navigation
Jump to search
m |
Tag: visualeditor |
||
| Line 1: | Line 1: | ||
| − | + | {| class="wikitable" style="text-align:center; width:100%;" {| | |
| − | !colspan="4 | + | ! colspan="4" style="color:white; font-size:125%; background-color:#31a354" align="center" |'''Section editors''' |
|- | |- | ||
| − | |style="background-color:#F0F0F0; width:15%"|[[File:Shruti.jpg|frameless|upright=0.3|center]] | + | | style="background-color:#F0F0F0; width:15%" |[[File:Shruti.jpg|frameless|upright=0.3|center]] |
| − | |style="width:35%"|<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MBBS, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn] | + | | style="width:35%" |<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MBBS, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn] |
| − | |style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] | + | | style="background-color:#F0F0F0; width:15%" |[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] |
| − | |style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big> | + | | style="width:35%" |<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big> |
|- | |- | ||
|} | |} | ||
| − | {|style="float:right; margin-right: 5px;" | + | {| style="float:right; margin-right: 5px;" |
|- | |- | ||
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> | ||
| Line 17: | Line 17: | ||
To be completed | To be completed | ||
=All lines of therapy= | =All lines of therapy= | ||
| − | + | ==Argatroban monotherapy== | |
| + | {| class="wikitable" | ||
| + | !Study | ||
| + | !Evidence | ||
| + | !Comparator | ||
| + | !Efficacy | ||
| + | |- | ||
| + | |[https://www.ncbi.nlm.nih.gov/pubmed/11294800 Lewis et al. 2001] | ||
| + | |Prospective, historical control | ||
| + | |Multiple | ||
| + | |Reduced all-cause death, all-cause amputation, and new thrombosis | ||
| + | |} | ||
| + | |||
| + | === Anticoagulation === | ||
| + | * Argatroban 2 ug/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 3.0 times baseline value. | ||
| + | |||
| + | == References == | ||
| + | B.E. Lewis, D.E. Wallis, S.D. Berkowitz, W.H. Matthai, J. Fareed, J.M. Walenga, J. Bartholomew, R. Sham, R.G. Lerner, Z.R. Zeigler, P.K. Rustagi, I.K. Jang, S.D. Rifkin, J. Moran, M.J. Hursting, J.G. Kelton, for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with Heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843. [https://www.ahajournals.org/doi/abs/10.1161/circ.103.14.1838 link to original article.] [https://www.ncbi.nlm.nih.gov/pubmed/11294800 PubMed.] | ||
[[Category:Heparin-induced thrombocytopenia (HIT) regimens]] | [[Category:Heparin-induced thrombocytopenia (HIT) regimens]] | ||
Revision as of 14:42, 9 September 2018
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
0 regimens on this page
0 variants on this page
|
Guidelines
To be completed
All lines of therapy
Argatroban monotherapy
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Lewis et al. 2001 | Prospective, historical control | Multiple | Reduced all-cause death, all-cause amputation, and new thrombosis |
Anticoagulation
- Argatroban 2 ug/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 3.0 times baseline value.
References
B.E. Lewis, D.E. Wallis, S.D. Berkowitz, W.H. Matthai, J. Fareed, J.M. Walenga, J. Bartholomew, R. Sham, R.G. Lerner, Z.R. Zeigler, P.K. Rustagi, I.K. Jang, S.D. Rifkin, J. Moran, M.J. Hursting, J.G. Kelton, for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with Heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843. link to original article. PubMed.